Study to Explore the Effects of Two Hour Inhalation of Ultrafine Carbon Black Particles on Airway Inflammation in Asthmatics

Inclusion criteria

• Male and female subjects, aged 18-45 years.
• Women will be considered for inclusion if they are:

• Not pregnant, as confirmed by a pregnancy test and not nursing.
• Not of child-bearing capacity (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meets clinical criteria for menopause and has been amenorrheal for more than 1 year prior to the screening visit).
• Of child-bearing capacity and using a highly effective method of contraception during the entire study (vasectomised partner, sexual abstinence [the lifestyle of the female should be such that there is complete abstinence from intercourse two weeks prior to the first dose of study medication until at least 72 hours after treatment], implants, injectables, combined oral contraceptives, hormonal intrauterine devices [IUDs]).
• Physician diagnosis of mild intermittent seasonal asthma
• Non-smokers, or ex-smokers
• Forced expiratory volume in 1 second (FEV1) > 80% of the predicted value
• Positive skin prick test for grass mix at or within 12 months prior to the screening visit
• Able and willing to give written informed consent to take part in the study
• Available to complete all study measurements
• Able to restrain from particle rich atmosphere (e.g. passive cigarette smoke) within 1 week before exposure to UFP or clean air

Exclusion criteria

• Infections of the respiratory tract within the last month
• Past or present disease which, as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
• Pathological findings in safety laboratory tests
• Subjects with clinically relevant infection or known ongoing clinically relevant inflammatory process
• Suspected hypersensitivity to any ingredients of the medication involved with bronchoscopy (bronchodilators, sedatives and local anaesthetics)
• Specific immunotherapy (SIT) within two years prior to the study
• Administration of oral, injectable, or dermal corticosteroids according to 9.2
• Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment
• Risk of non-compliance with study procedures
• Participation in another clinical trial 30 days prior to enrolment
• Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.
• Unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., language problems, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study